PubMed · 2022
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Wilding JPH, Batterham RL, Calanna S, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab.
Diabetes Obes Metab
Source: https://pubmed.ncbi.nlm.nih.gov/35441470/
Last reviewed . By the PeptIQ team.
Peptides linked in PeptIQ Wiki
This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.